ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 189

Indocyanine Green (ICG) -Enhanced Fluorescence Optical Imaging (FOI) in Patients with Active Rheumatoid Arthritis; A Comparative Study with Ultrasound and Association with Biomarkers

Shin-ya Kawashiri1,2, Ayako Nishino3, Masataka Umeda3, Shoichi Fukui1, Yoshikazu Nakashima3, Naoki Iwamoto1, Kunihiro Ichinose1, Hideki Nakamura1, Tomoki Origuchi4, Kiyoshi Aoyagi2 and Atsushi Kawakami3, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 4Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, Imaging, inflammatory arthritis, rheumatoid arthritis (RA) and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Indocyanine green (ICG) -enhanced fluorescence optical imaging (FOI) is a novel diagnostic tool for the assessment of inflammatory
arthritis through visualizing vascular beds. Ultrasound (US) can detect joint
injury of rheumatoid arthritis (RA) with high sensitivity. We previously
reported that US synovitis scores correlate with
serum biomarkers such as angiogenesis factors.
This study is undertaken to
explore the utility of FOI comparing with US and serum biomarkers.

Methods:

Twenty-five active RA
patients (mean disease durations 7.5 years and DAS28-ESR 5.90) who fulfilled
2010 RA classification criteria were consecutively enrolled in this study. They gave their informed consent to be subjected
to the protocol that was approved by the Institutional Review Board of Nagasaki
University. Both FOI and US were performed at the same
day. Interpretation of FOI images using Xiralite
system was done for an early phase (phase 1, P1), an intermediate phase (phase
2, P2), a late phase (phase 3, P3) and an early electronically generated
composite image (CI) from 18 joints including bilateral 2nd -5th
metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints and wrist joints (Figure 1).
The same joints were scored by
gray scale (GS) and power Doppler (PD) by US. FOI assessments of P1, P2,
P3, CI as well as GS score and PD score were semi-quantitatively classified from 0 to 3 as
described (total scores of each parameter are 0 to 54 from the 18 joints,
respectively). Bone erosion was also assessed by US. Forty-five
serum biomarkers at the time of FOI/US examinations
were measured by multi-suspension cytokine array.

Results:

Positive
finding (
≥ grade 1)
were found in 122, 206, 140, 139 and 148 out of 450 joints in P1, P2, P3, CI
and PDUS, respectively.
FOI scores were significantly high in the joints where bone
erosion was detected by US as compared to those without bone erosion (p<0.0001).
Among individual patients, each total FOI scores clearly correlated with both
GS and PD scores (r=0.46-0.71) as well as with DAS28-ESR (r=0.66-0.72). In
addition, serum IL-6, VEGF and TNF- correlated with FOI scores.

Comparing with PDUS ≥ grade 1 or PDUS ≥ grade 2 as the reference, the
positive predictive value (PPV) of FOI scores (≥ grade 1) in whole joints
were 82.0 (P1), 66.5 (P2), 75.7 (P3) and 76.3 % (CI) toward PDUS ≥ grade
1 or 66.4 (P1), 44.7 (P2), 54.3 (P3) and 56.1 % (CI) toward PDUS ≥ grade
2, respectively.

Conclusion:

Since FOI scores correlate with US scores as well as
serum biomarkers, FOI is considered to detect joint inflammation of RA patients
with high accuracy. However, the significance of each phase of FOI may be
different and need to be further clarified.



Disclosure: S. Y. Kawashiri, None; A. Nishino, None; M. Umeda, None; S. Fukui, None; Y. Nakashima, None; N. Iwamoto, None; K. Ichinose, None; H. Nakamura, None; T. Origuchi, None; K. Aoyagi, None; A. Kawakami, None.

To cite this abstract in AMA style:

Kawashiri SY, Nishino A, Umeda M, Fukui S, Nakashima Y, Iwamoto N, Ichinose K, Nakamura H, Origuchi T, Aoyagi K, Kawakami A. Indocyanine Green (ICG) -Enhanced Fluorescence Optical Imaging (FOI) in Patients with Active Rheumatoid Arthritis; A Comparative Study with Ultrasound and Association with Biomarkers [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/indocyanine-green-icg-enhanced-fluorescence-optical-imaging-foi-in-patients-with-active-rheumatoid-arthritis-a-comparative-study-with-ultrasound-and-association-with-biomarkers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/indocyanine-green-icg-enhanced-fluorescence-optical-imaging-foi-in-patients-with-active-rheumatoid-arthritis-a-comparative-study-with-ultrasound-and-association-with-biomarkers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology